Selective Androgen Receptor Modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Narayanan, Ramesh ^a,b   Ahn, Sunjoo ^a   Cheney, Misty D ^a   Yepuru, Muralimohan ^a   Miller, Duane D ^a   Steiner, Mitchell S ^a   Dalton, James T ^a  

^a GTx Inc   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; COLLAGENASE 3; ENOBOSARM; GTX 019; GTX 024R; GTX 025; GTX 026; GTX 027; INTERLEUKIN 16; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER INHIBITION; CELL INTERACTION; COCULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MDA MB 231 CELL LINE; MDA MB 453 CELL LINE; MESENCHYMAL STEM CELL; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PARACRINE SIGNALING; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STABLE EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; TUMOR WEIGHT; WEIGHT GAIN; WILD TYPE; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; NEOPLASM METASTASIS; PARACRINE COMMUNICATION; RECEPTORS, ANDROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904965441     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103202     Document Type: Article

References (45)

1. American Cancer Society (2014) Cancer Facts & Figures 2014. American Cancer Society.
2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, et al. (2011) Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747.
3. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, et al. (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4: 209-229.
4. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741.
5. Stebbing J, Ellis P (2012) An overview of drug development for metastatic breast cancer. Br J Nurs 21: S18-22.
6. Peters KM, Edwards SL, Nair SS, French JD, Bailey PJ, et al. (2012) Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. BMC Cancer 12: 132.
7. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, et al. (2014) Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest 124: 859-870.
8. Garay JP, Park BH (2012) Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res 2: 434-445.
9. Kennedy BJ (1958) Fluoxymesterone therapy in advanced breast cancer. N Engl J Med 259: 673-675.
10. Adair FE, Herrmann JB (1946) The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg 123: 1023-1035.
11. Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, et al. (2005) Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res 65: 8487-8496. (Pubitemid 41330617)
12. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23: 205-212.
13. Narita D, Raica M, Suciu C, Cimpean A, Anghel A (2006) Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer. Folia Histochem Cytobiol 44: 165-172. (Pubitemid 44131983)
14. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, et al. (2013) Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype. Ann Surg Oncol 21: 361-367.
15. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, et al. (2013) Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. Clin Cancer Res 19: 5505-5512.
16. Narita D, Cimpean AM, Anghel A, Raica M (2006) Prostate-specific antigen value as a marker in breast cancer. Neoplasma 53: 161-167.
17. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, et al. (1996) Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171-178. (Pubitemid 26283509)
18. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, et al. (1995) Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104-2110.
19. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120: 725-731. (Pubitemid 37339680)
20. Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, et al. (2007) Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 24: 328-335. (Pubitemid 46084804)
21. Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, et al. (2005) Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 146: 4887-4897. (Pubitemid 41446627)
22. Kearbey JD, Gao W, Fisher SJ, Wu D, Miller DD, et al. (2009) Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats. Pharm Res 26: 2471-2477.
23. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, et al. (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2: 153-161.
24. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, et al. (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62: 265-279.
25. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, et al. (2013) Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 14: 335-345.
26. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563. (Pubitemid 47525152)
27. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, et al. (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47: 570-584.
28. Narayanan R, Yepuru M, Szafran AT, Szwarc M, Bohl CE, et al. (2010) Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res 70: 842-851.
29. Yang CH, Yue J, Fan M, Pfeffer LM (2010) IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 70: 8108-8116.
30. Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, et al. (2013) Steroidogenic Enzyme AKR1C3 is a Novel Androgen Receptor-Selective Coactivator That Promotes Prostate Cancer Growth. Clin Cancer Res.
31. Narayanan R, Adigun AA, Edwards DP, Weigel NL (2005) Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol 25: 264-277. (Pubitemid 40039817)
32. Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, et al. (2002) Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci U S A 99: 7940-7944. (Pubitemid 34650984)
33. Smith CL, O'Malley BW (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45-71. (Pubitemid 38292038)
34. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, et al. (2008) Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 22: 2448-2465.
35. Chen J, Hwang DJ, Chung K, Bohl CE, Fisher SJ, et al. (2005) In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology 146: 5444-5454. (Pubitemid 41653059)
36. Razandi M, Pedram A, Jordan VC, Fuqua S, Levin ER (2013) Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 32: 3274-3285.
37. Rizza P, Barone I, Zito D, Giordano F, Lanzino M, et al. (2014) Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res 16: R21.
38. Hild SA, Attardi BJ, Koduri S, Till BA, Reel JR (2010) Effects of synthetic androgens on liver function using the rabbit as a model. J Androl 31: 472-481.
39. Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10: 90-99.
40. Fearon KH (2013) Selective androgen receptor modulators in cancer cachexia? Lancet Oncol 14: 271-272.
41. Grattarola R, Secreto G, Recchione C (1975) Androgens in breast cancer. III. Breast cancer recurrences years after mastectomy and increased androgenic activity. Am J Obstet Gynecol 121: 169-172.
42. Grattarola R, Secreto G, Recchione C, Castellini W (1974) Androgens in breast cancer. II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women. Am J Obstet Gynecol 118: 173-178.
43. Furuya K, Yamamoto N, Ohyabu Y, Makino A, Morikyu T, et al. (2012) The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats. Biol Pharm Bull 35: 1096-1104.
44. Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, et al. (2011) Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 118: 5540-5549.
45. Swamydas M, Ricci K, Rego SL, Dreau D (2013) Mesenchymal stem cellderived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adh Migr 7: 315-324.